Welcome to our dedicated page for Alr Technologies SEC filings (Ticker: ALRTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ALR Technologies SG Ltd (ALRTF) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. ALR Technologies files reports such as Form 20-F and Form 6-K under the Securities Exchange Act of 1934, presenting condensed interim consolidated financial statements, management’s discussion and analysis, risk factors, and information on legal proceedings, controls and procedures, and other required items.
In its filings, ALR Technologies describes itself as a data management company focused on diabetes care. The documents outline the structure and components of the ALRT Diabetes Solution, including an FDA-cleared and HIPAA compliant diabetes management system, a Predictive A1C algorithm, and an FDA-cleared Insulin Dosing Adjustment program. The filings also discuss the company’s development of the GluCurve Pet CGM for the animal health market, which bundles animal-specific diabetes management software with continuous glucose monitors designed for dogs and cats.
Financial statements in these filings detail operating expenses, interest expense, net losses, cash flows, and shareholders’ deficit, along with notes on going concern considerations, debt obligations, and related-party financing. Users can review how ALR Technologies accounts for product development costs, selling, general and administrative expenses, and financing activities such as lines of credit, promissory notes, and warrants. The filings also disclose corporate structure information, including the incorporation of subsidiaries and the redomicile merger that made ALR Technologies SG Ltd the parent company.
Stock Titan’s platform surfaces these filings as they are made available through EDGAR and pairs them with AI-powered summaries to help readers interpret key sections. Users can quickly identify disclosures on topics such as the company’s diabetes management platform, GluCurve Pet CGM development, capital structure changes, and going concern risks without reading every page of each report.
ALR Technologies SG Ltd. CEO and director Sidney Chan filed an initial Form 3 showing his and related holdings in the company. He reports direct ownership of 189,845,000 Ordinary Shares and indirect ownership of 193,653,482 Ordinary Shares held by his spouse, Christine Kan. The filing also lists large warrant positions over Ordinary Shares with exercise prices between $0.0100 and $0.0200 per share, expiring on December 31, 2026, including 4,210,001,000 underlying shares held directly and 700,000,500 underlying shares held indirectly through his spouse.
ALR Technologies SG Ltd. reports that on December 31, 2026 it modified certain share purchase warrants held by two senior insiders. The company extended the expiry date of 4,910,001,500 warrants held by CEO and Chairman Sidney Chan and VP and director Christine Kan from December 31, 2025 to December 31, 2026. Each warrant is exercisable into one ordinary share at an exercise price of $0.002 per share. This change keeps a large block of low-priced warrants in place for an additional year, preserving potential equity participation for these executives.
ALR Technologies SG Ltd. reports a deepening loss and severe liquidity strain for the six months ended June 30, 2025. Net loss widened to about $10,770,000 from $6,028,000, mainly because interest expense soared to $9,367,270, including $8,187,123 of non-cash share-based compensation from modifying warrants held by the CEO and VP. Core operating expenses actually fell 46% to roughly $1,139,000 as product development, professional, and administrative costs decreased.
The balance sheet is highly stressed. Current liabilities were $38,368,906 versus total assets of only $31,002, leaving a working capital deficit of about $38,338,000 and shareholders’ deficit of $38,337,904. The company had cash of just $1,738 and relies heavily on related-party funding, including $21,164,886 of lines of credit and a $3,822,081 loan. Management discloses substantial doubt about its ability to continue as a going concern, with $11,222,000 of promissory notes and related interest in default and prior default judgments outstanding.
ALR Technologies SG Ltd. filed a report as a foreign private issuer to share a recent company announcement. The filing states that on December 8, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1.
The press release announced the relaunch of the company’s GluCurve Pet CGM, a continuous glucose monitoring product for pets. This report mainly serves to make that product update publicly available to investors through the SEC’s disclosure system.